Epirubicin
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Jennifer Crombie, MDPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Obinutuzumab National Cancer Institute (NCI) | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Venetoclax National Cancer Institute (NCI) | Phase 2 | CCC |
Pembrolizumab Jennifer Crombie, MD | Phase 2 | CCC |
cc-5013 National Cancer Institute (NCI) | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →